Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

Clinical Development. In addition, Judith A. Fox, Ph.D., has been promoted to Vice President, Product and Preclinical Development and Glenn C. Michelson, M.D., has been promoted to Vice President, Clinical Strategy.

To date, voreloxin has demonstrated objective responses in both solid and hematologic tumors and has been consistently well tolerated in multiple clinical trials. Sunesis is currently conducting Phase 2 clinical trials of voreloxin as a single agent for the treatment of platinum-resistant ovarian cancer and previously untreated acute myeloid leukemia (AML), as well as a Phase 1b clinical trial of voreloxin in combination with cytarabine in relapsed/refractory AML. Data recently reported at the 44th ASCO Annual Meeting in the Phase 2 ovarian cancer trial demonstrated that 48 percent of platinum-resistant ovarian cancer patients treated at a dose of 48 mg/m2 once every 21 days achieved disease control, defined as stable disease for 90 days or more or a complete or partial response. Preliminary median progression- free survival in this group of patients was 13 weeks at this dose; twenty- three patients at this dose remained on study as of May 12, 2008. Later this month, at the European Hematology Association Congress, Sunesis will report updated data on voreloxin's activity alone, and interim data on voreloxin's activity in combination with cytarabine for the treatment of AML.

Sunesis continues ongoing trials in its earlier-stage clinical programs, including the Phase 1 dose-escalation study of its cyclin-dependent kinase inhibitor, SNS-032, and its pan-Aurora kinase inhibitor, SNS-314, and expects to report data from these clinical trials this year. The company plans to seek a development partner to support advanced clinical trials of SNS-314. Future development of SNS-032 will depend on achieving positive results from the ongoing trial.

With the closing of its internal discovery research activities, Sunesis will also explore opportun
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, ... interactive music products, today announced that it has ... leading manufacturer and supplier of innovative prosthetic, orthotic ... As part of the agreement, RSL Steeper will ... solution specifically configured for use within UK residential ...
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014  RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced completion of enrollment in its ... from the 3-month observations confirmed the 1-month findings ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... NEW YORK, March 20, 2012  Faruqi & Faruqi, ... investigating potential securities fraud at ZELTIQ Aesthetics, Inc. ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO  ) Faruqi ... misled investors by failing to disclose material information ...
... WASHINGTON, March 20, 2012  At a public event ... Fight AIDS, Tuberculosis and Malaria and Friends of ... spotlighted the contributions of public-private partnerships to the ... delivery, to supplying much-needed resources, to mobilizing consumer ...
Cached Medicine Technology:Faruqi & Faruqi, LLP Announces Investigation of ZELTIQ Aesthetics, Inc. 2Global Fund Celebrates Efforts of Partners Chevron, The Coca-Cola Company, (RED) and PEPFAR at Capitol Hill Event 2Global Fund Celebrates Efforts of Partners Chevron, The Coca-Cola Company, (RED) and PEPFAR at Capitol Hill Event 3Global Fund Celebrates Efforts of Partners Chevron, The Coca-Cola Company, (RED) and PEPFAR at Capitol Hill Event 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... and vision assessments provided by InfantSEE(R) ProgramCHARLESTON, W.Va., ... of children with eye and vision problems across ... appointments to no-cost, comprehensive eye and vision assessments ... age through InfantSEE(R). InfantSEE(R), a public health program ...
... New York, N.Y. April 28, 2009 Peripheral arterial disease ... plaque and blood supply to the legs is reduced, affects eight ... because it can limit the ability to walk and exercise, it ... increases the chance of having a heart attack or stroke. Coronary ...
... text to speech instantly converts Word, PDF, PowerPoint, Excel and Web ... ... NJ (PRWEB) April 28, 2009 -- iSpeech.org, text to speech software ... to anyone using the Box.net platform. The integration allows Box customers ...
... Health Care ReformWASHINGTON, April 28 Private-sector strategies ... an essential component of comprehensive health care reform, ... AHIP hosted a press conference today to highlight ... to reward quality and spur improvement."There is widespread ...
... membership organizations today released Guidelines for Patient Centered ... the American Academy of Family Physicians (AAFP), the ... of Physicians (ACP) and the American Osteopathic Association ... pediatrician, family physician, internist and osteopathic physician members ...
... studies have shown that depression is associated with an increased ... clear. , Now, researchers at Rush University Medical Center have ... fat, the kind of fat packed between internal organs at ... risk of cardiovascular disease and diabetes. , The study is ...
Cached Medicine News:Health News:West Virginia Optometrists Partner With Sens. Byrd and Rockefeller, U.S. House Leaders in Improving Infant Eye and Vision Care 2Health News:West Virginia Optometrists Partner With Sens. Byrd and Rockefeller, U.S. House Leaders in Improving Infant Eye and Vision Care 3Health News:West Virginia Optometrists Partner With Sens. Byrd and Rockefeller, U.S. House Leaders in Improving Infant Eye and Vision Care 4Health News:West Virginia Optometrists Partner With Sens. Byrd and Rockefeller, U.S. House Leaders in Improving Infant Eye and Vision Care 5Health News:West Virginia Optometrists Partner With Sens. Byrd and Rockefeller, U.S. House Leaders in Improving Infant Eye and Vision Care 6Health News:West Virginia Optometrists Partner With Sens. Byrd and Rockefeller, U.S. House Leaders in Improving Infant Eye and Vision Care 7Health News:West Virginia Optometrists Partner With Sens. Byrd and Rockefeller, U.S. House Leaders in Improving Infant Eye and Vision Care 8Health News:Arterial disease of the leg frequently overlooked in patients with heart disease 2Health News:iSpeech.org Makes Box.net Talk Aloud 2Health News:New Health Plan Payment Models Are Improving Patient Quality and Safety 2Health News:New Health Plan Payment Models Are Improving Patient Quality and Safety 3Health News:New Health Plan Payment Models Are Improving Patient Quality and Safety 4Health News:Guidelines for medical home demonstrations released by major physician groups 2Health News:Guidelines for medical home demonstrations released by major physician groups 3Health News:Depression linked with accumulation of visceral fat 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: